top of page

Publication Highlights

june 2024

Antibody Immunogenicity

Immunogenicity of biologics used in the treatment of asthma

May 2024

Antibody discovery

Eukaryotic ribosome display for antibody discovery: A review

Dec 2023

MS Therapy

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis

July 2023

INFECTION & IMMUNOBIOLOGY

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

MARCH 2023

MICROBIAL PATHOGENESIS

Exploring the “N-Terminal Anchor” Binding Interface of the T3SS Chaperone–Translocator Complexes from P. aeruginosa

JUNE 2022

infection & immunobiology

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

december 2021

MS THERAPY

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in MS

October 2021

infection & immunobiology

COVID-19 vaccine response in people with multiple sclerosis

Summer 2021

Immunogenicity

Immunogenicity of biologics used in the treatment of moderate to severe psoriasis

summer 2021

immunogenicity

Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review

bottom of page